Remove Capital Raising Remove Medical Remove Valuation
article thumbnail

PCE Welcomes Bradley Scharfenberg as Vice President, M&A

PCE

At PCE, he’ll lead execution for sell-side and buy-side engagements, recapitalizations, and capital raises, with a strong focus on expanding our healthcare investment banking practice. Joining PCE is an exciting opportunity to bring my healthcare experience to a team that truly values long-term client relationships,” said Brad.

M&A 52
article thumbnail

Recap: 2023 Midwest M&A/Private Equity Forum

Focus Investment Banking

In particular, companies in the logistics space likely will enjoy an enhancer to valuation if they utilize cutting edge technology. Nevertheless, owners are still holding out for what they perceive as the higher valuations of the previous few years.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Sky Definitely Is Not Falling…At Least Not Yet

Sica Fletcher

No one really knows how the pandemic will play out from a medical, economic, political, and societal perspective. The answer relates to private equity and the availability of capital to fund acquisitions and the need to deploy this capital. We face a future of uncertainty. PE-backed deal flow declined somewhat in 2019.

article thumbnail

Biotech Hedge Funds: A Match Made in Heaven

Mergers and Inquisitions

In technology, as a startup keeps raising capital, it normally does so at gradually higher valuations as its customers, users, and revenue grow. But in biotech, companies valuations often remain close to their total capital raised until much later in the process (i.e., or Ph.D.),

Funds 64